MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression aft ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

Modifi Bio’s founders discuss the journey from developing a cancer treatment drug to being acquired by Big Pharma.

It’s a good place to develop, with generous government incentives, including a Research & Development (R&D) rebate. There are ...

She previously served as Chief Executive Officer at Harpoon Therapeutics until the company's acquisition by Merck in early 2024. In addition to Ms. Eastland's appointment, Ingmar Bruns, M.D., has been ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...